Indaptus Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Indaptus Therapeutics, Inc. (Nasdaq: INDP) on January 2, 2026, reporting events occurring on December 29, 2025. The company is incorporated in Delaware and operates in the biotechnology sector.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes.
Material Changes
On December 29, 2025, three members of the Board of Directors—Michael Newman, Mark Gilbert, and Anthony Maddaluna—resigned. Their resignations are effective upon the approval of David Lazar's nominees at the Company's next stockholders' meeting. The Company stated these departures were not the result of any disagreement regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. The primary risk disclosed relates to the pending change in Board composition pending shareholder approval.
Key Investor Verification Points
- Verify the date and agenda of the next stockholders' meeting to confirm the timing of the Board transition.
- Confirm the identities and qualifications of the nominees proposed by David Lazar.
- Review subsequent filings to ensure no undisclosed disagreements regarding the resignations emerge.